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Abstract
Introduction: Interleukin (IL)-32 is an inflammatory cytokine induced by Mycobacterium tuberculosis and
Mycobacterium bovis in a variety of cell types and discovered in the synovial of patients with rheumatoid arthritis
(RA). Thymic stromal lymphopoietin (TSLP) play several roles in the pathogenesis of RA. However, the role of IL-32
and TSLP in RA has not been elucidated.
Methods: We evaluated the specific mechanism of between IL-32 and TSLP in RA using human monocyte cell
line, THP-1 cells.
Results: Here we documented for the first time that IL-32 highly increased TSLP production in THP-1 cells and
human blood monocytes. TSLP expression was induced by IL-32 via activation of caspase-1 and nuclear factor-B.
TSLP produced by IL-32 increased differentiation of monocytes but depletion of TSLP prevented differentiation of
monocytes into macrophage-like cells. Chondroprotective drugs such as chondroitin sulfate (CS) and the traditional
Korean medicine, BaekJeol-Tang (BT) decrease production of TSLP and activation of caspase-1 and nuclear factor-B.
In addition, CS and BT inhibited IL-32-induced monocytes differentiation.
Conclusions: Taken together, IL-32 and TSLP are important cytokines involved in the development of RA. The effects
of CS and BT were associated with the downregulation of TSLP and caspase-1 through negative regulation of IL-32
pathways in RA.
Introduction
Rheumatoid arthritis (RA) is characterized by a chronic
inflammation of synovial joints that leads to a progressive
destruction of articular and periarticular structures, caus-
ing severe morbidity and disability [1]. In RA, the exten-
sive infiltration of inflammatory cells into the synovium
and the tumor-like proliferation of RA synovial fibroblasts
(RASF) cause the formation of a hyperplastic pannus,
which aggressively invades and destroys underlying carti-
lage and bone. Until now, the role of macrophages, T and
B cells, neutrophils, and RASF in the pathophysiology of
RA have been examined extensively [2-6].
Interleukin (IL)-32 is a recently described cytokine pro-
duced by T lymphocytes, natural killer cells, epithelial
cells, mast cells, keratinocytes, eosinophils, and blood
monocytes [7-11] and was discovered in the synovial of
patients with rheumatoid arthritis but not osteoarthritis
[12]. IL-32 was induced by Mycobacterium tuberculosis
and Mycobacterium bovis bacillus Calmette-Guérin as well
as by either lipopolysaccharide (LPS) or mycobacteria [13].
Moreover, IL-32 production induced by M. tuberculosis is
dependent on endogenous interferon-g (IFN-g) [13]. A
recent study demonstrated that overexpression of the
inflammatory mediator, cyclooxygenase 2 resulted in
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increased IL-32 levels [14]. IL-32 induces the production
of tumor necrosis factor (TNF)-a, IL-1b, IL-6, and IL-8 by
means of the activation of nuclear factor (NF)-B, p38
mitogen-activated protein kinase (MAPK), and caspase-1
[7,8,11]. IL-32 also modulates the signals induced by speci-
fic Toll-like receptors (TLRs) and nucleotide oligomeriza-
tion domain (NOD) ligands. IL-32 synergized with NOD1
and NOD2 ligands for the synthesis of IL-1b and IL-6 via
activation of caspase-1 [8].
Thymic stromal lymphopoietin (TSLP) is associated
with RA, allergic rhinitis and atopic dermatitis [15-17]. It
might initiate T helper cell type 2 (Th2) polarization
through an OX40-dependent mechanism that affects den-
dritic cells (DC) activity [17,18]. Signaling of cells by TSLP
requires IL-7 receptor [19]. and a distinctive receptor sub-
unit, the TSLP receptor (TSLPR), which is expressed by
myeloid DC, monocytes, preactivated T cells, natural killer
cells, and mast cells [18,20-22]. In humans, TSLP potently
stimulates myeloid DC, with upregulated expression of
CD40, CD80, CD86, OX40L, and CD83 and production of
chemokines, including thymus and activation-regulated
chemokine and macrophage-derived chemokine [23,24].
TSLP was expressed by TNF-a and IL-1b in human air-
way smooth muscle cells via MAPK, p38 and extracellular
signal-regulated kinase (ERK) signaling pathway [25].
Recently, we reported that TSLP was expressed and pro-
duced by caspase-1 and NF-B activation in mast cells
[26].
Although the above-mentioned findings indicate a
likely role of IL-32 and TSLP in RA, the specific mechan-
ism of between IL-32 and TSLP have not previously been
studied. In this study, we report that IL-32 induces TSLP
production and monocyte-to-macrophage differentiation
through caspase-1. We also investigated the effect of use-
ful therapeutic agents in RA, chondroitin sulfate (CS)
and the traditional Korean medicine, BaekJeol-Tang





trazolium bromide (MTT), bicinchoninic acid, caspase-1
inhibitor (CI), pyrrolidine dithiocarbamate (PDTC), lipo-
polysaccharide (LPS), dimethyl sulfoxide (DMSO), CS, and
caspase-1 inhibitor from Sigma-Aldrich (St. Louis, MO,
USA); recombinant IL-32, recombinant TSLP, caspase-1
assay kit, and recombinant caspase-1 from R&D Systems
(Minneapolis, MN, USA); NF-B, actin, histone, and cas-
pase-1 antibodies from Santa Cruz Biotechnology (Santa
Cruz, CA, USA); CD11b and CD14 antibodies from
eBioscience (San Diego, CA, USA); TSLP SMART pool
from Dharmacon Inc. (Chicago, IL, USA).
Preparation of BT and CS
BT is composed of shark cartilage (24 g), Atractylodis
Rhizoma (Atractylodes lancea De Candolle, 8 g), Phello-
dendri Cortex (Phellodendron amurense Ruprecht, 8 g),
and Sophora Radix (Sophora flavescens Solander ex
Aiton, 8 g). BT (voucher number 201101) was obtained
from TeunTeunMaDi Korean Medical Clinic (Seoul,
Republic of Korea) and identified by Dr Hyung-Min Kim
of the College of Oriental Medicine, Kyung Hee Univer-
sity. An extract of BT was prepared by decocting the
dried prescription of herbs with boiling distilled water
(48 g/l). The product was filtered, lyophilized and kept at
4°C. The yield of dried product from starting materials
was about 35.6%. CS is a major component of shark carti-
lage. The samples were dissolved in distilled water and
then filtered through a 0.22 μm syringe filter.
Cells
Human monocyte cell line, THP-1 was obtained from the
American Type Culture Collection (TIB-202; Manassas,
VA, USA). THP-1 cells were cultured in RPMI 1640 sup-
plemented with 10% fetal bovine serum (FBS) and 2 mM
glutamine and were maintained at a concentration
between 2 and 10 × 105 cells per milliliter.
Isolation of peripheral blood mononuclear cells (PBMCs)
PBMCs were isolated from healthy human volunteers. The
donors were free of prescribed and over-the-counter med-
ications. After informed consent, PBMCs from heparinized
venous blood were isolated with Ficoll gradient centrifuga-
tion according to the manufacturer’s specification (Sigma-
Aldrich, MO, USA). This study was approved by the local
ethics committee of Kyung Hee University Hospital in
Seoul, Republic of Korea (KMC IRB 1222-06)
TSLP assay
THP-1 cells were treated with various concentrations of
IL-32 for 24 h. The production of TSLP was measured
from cells culture supernatant according to the manufac-
turer’s specifications (R&D Systems, Minneapolis, MN,
USA).
Reverse transcription PCR analysis
Using an easy-BLUE™ RNA extraction kit (iNtRON Bio-
technology, Republic of Korea), we isolated the total
RNA from THP-1 cells in accordance with the manufac-
turer’s specification. The concentrations of total RNA in
the final elutes were determined by spectrophotometer.
Total RNA (1 mg) was heated at 65°C for 10 min and
then chilled on ice. Each sample was reverse-transcribed
to cDNA for 90 min at 37°C using a cDNA synthesis kit
(Amersham Pharmacia Biotech, Piscataway, NJ, USA).
The PCR was performed with the following primer for
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human TSLP (5’ TAT GAG TGG GAC CAA AAG TAC
CG 3’; 5’ GGG ATT GAA GGT TAG GCT CTG G 3’)
and GAPDH (5’CAA AAG GGT CAT CAT CTC TG 3’;
5’CCT GCT TCA CCA CCT TCT TG 3’). The annealing
temperature was 62°C for TSLP and GAPDH. Products
were electrophoresed on a 2% agarose gel and visualized
by staining with ethidium bromide.
Quantitative real-time PCR analysis
Quantitative real-time PCR was performed using a SYBR
Green Master Mix and the detection of mRNA was ana-
lyzed using an ABI StepOne Real-Time PCR System
(Applied Biosystems, Foster City, CA, USA). Primer
sequences for the reference gene GAPDH and the genes
of interest were as follows: GAPDH (5’TCG ACA GTC
AGC CGC ATC TTC TTT 3’; 5’ACC AAA TCC GTT
GAC TCC GAC CTT 3’); human TSLP (5 CCC AGG
CTA TTC GGA AAC TCA G 3’; 5’ CGC CAC AAT CCT
TGT AAT TGT G 3’); human CD11b (5’ACG TAA ATG
GGA CAA GCT G 3’; 5’GAT CCT GAG GTT CCG TGA
AA 3’); human CD14 (5’ACT TGC ACT TTC CAG CTT
GC 3’; 5’GCC CAG TCC AGG ATT GTC AG 3’). Typical
profile times used were the initial step, 95°C for 10 min
followed by a second step at 95°C for 15 s and 60°C for 30
s for 40 cycles with a melting curve analysis. The level of
target mRNA was normalized to the level of the GAPDH
and compared with the control. Data were analyzed using
the ΔΔCT method.
Caspase-1 enzymatic activity assay
Caspase-1 enzymatic activity was measured according to
the manufacturer’s specification by using a caspase assay
kit.
Western blot analysis
The stimulated cells were lysed and separated through
10% SDS-PAGE. After electrophoresis, the protein was
transferred to nitrocellulose membranes and then the
membranes were blocked and incubated with primary
and secondary antibodies. Finally, the protein bands were
visualized by an enhanced chemiluminesence assay pur-
chased from Amersham Co. (Newark, NJ, USA) following
the manufacturer’s instructions.
Transient transfection and luciferase assay
For the transfection, we seeded THP-1 cells (1 × 107) in a
100 mm culture dish. We then used Lipofectamine™
2000 purchased from Invitrogen (Carlsbad, CA, USA) to
transiently transfect pNF-B luciferase (LUC) and
pSV40-LUC reporter gene constructs into THP-1 cells.
To measure the luciferase activity, we used a lumin-
ometer 1420 luminescence counter purchased from Per-
kin Elmer (Waltham, MA, USA) in accordance with the
manufacturer’s protocol. All the transfection experiments
were performed in at least three different experiments,
with similar results. The relative luciferase activity was
defined as the ratio of firefly luciferase activity to renilla
luciferase activity.
Analysis of monocyte surface antigens by flow cytometry
and confocal laser scanning microscopy
THP-1 cultured in the presence or absence of IL-32,
TSLP, CI, CS, and BT for 6 days were washed in fluor-
escence-activated cell sorter (FACS) buffer (phosphate-
buffered saline supplemented with 1% bovine serum
albumin and 0.1% NaN) and then incubated with 2 μl of
fluorescein isothiocyanate (FITC)-conjugated CD14 and
phycoerythrin (PE)-conjugated CD11b antibodies for
30 min at 4°C. After washing with FACS buffer, cells
were fixed with 1% (weight/volume) paraformaldehyde
for 30 min and then stored in the dark until analyzed by
flow cytometry. Cytofluorometry was performed with a
FACScan (Becton Dickinson, Mountain View, CA,
USA). All specimens were examined with a confocal
laser scanning microscope.
Statistical analysis
All results are expressed as the mean ± SEM. The statisti-
cal evaluation of the results was performed by an inde-
pendent t test and an ANOVA with a Tukey post hoc
test. The results are significant with a value of P < 0.05.
Results
Upregulation of TSLP production and mRNA expression in
IL-32-treated THP-1 cells
IL-32 and TSLP levels are increased in patients with RA
[12,15]. To identify the relationship between IL-32 and
TSLP in RA, we investigated whether the mRNA of TSLP
were expressed by IL-32 in THP-1 cells. When we stimu-
lated the THP-1 cells with IL-32 of various concentrations,
the TSLP mRNA was expressed (Figure 1A and 1B). LPS
also induced expression of TSLP mRNA. IL-32 signifi-
cantly increased TSLP production in a time-dependent
manner (Figure 1C). TSLP production was significantly
increased by IL-32 (0.1 and 1 μg/ml) in a dose-dependent
manner (Figure 1D, P < 0.05). In our previous work, we
reported that IL-32 produced IL-1b. IL-1b production was
assayed to test the activity of IL-32. IL-1b production was
significantly increased by IL-32 (Figure 1E, P < 0.05). IL-
32 (1 μg/ml) also significantly increased TSLP production
in PBMCs (Figure 1F, P < 0.05).
Caspase-1 and NF-B involvement in IL-32-induced TSLP
production and mRNA expression
Recently, we reported that TSLP was produced and
expressed by caspase-1 and NF-B activation in mast cells
[26]. To evaluate whether IL-32 increased caspase-1 and
NF-B activity in THP-1 cells, we performed Western blot
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analysis and caspase-1 assay. As shown in Figure 2A, IL-32
increased caspase-1 and NF-B activation. Caspase-1
activity increased by IL-32 was inhibited by caspase-1 inhi-
bitor (Figure 2B). TSLP and IL-1b production increased by
IL-32 (0.1 μg/ml) was dose-dependently inhibited by treat-
ment of caspase-1 inhibitor (Figure 2C, P < 0.05). NF-B
inhibitor, PDTC, inhibited IL-32-induced NF-B activa-
tion and TSLP mRNA expression (Figure 2D). LPS also
induced TSLP production through caspase-1 and NF-B
activation in THP-1 cells.
Role of caspase-1 in IL-32-induced macrophage-like cells
differentiation
Netea et al. reported that IL-32 induces differentiation of
monocytes into macrophage-like cells [27]. As shown in
Figure 3A, IL-32-treated cells appeared differentiated
into macrophages. In contrast, caspase-1 inhibitor
blocked IL-32-induced differentiation (Figure 3A). Next,
we performed detailed analyses of macrophage markers.
As shown in Figure 3B, IL-32 induced transcription of
both CD11b and CD14 mRNA but caspase-1 inhibitor
significantly reduced CD11b and CD14 mRNA levels in
THP-1 cells (Figure 3B). To observe the consistency of
the IL-32 effect on surface markers of the macrophage
phenotype, THP-1 cells were incubated with IL-32 for
6 days, and the protein expression of CD11b and CD14
was analyzed by FACS. As shown in Figure 3C, IL-32
induced a consistent increase in the protein expression of
both CD11b and CD14 compared with control cells incu-
bated with medium only. In contrast, caspase-1 inhibitor
reduced CD11b and CD14 protein expression (Figure
3C). When THP-1 cells were cultured for 6 days without
FBS, cell death was observed in PDTC-treated THP-1
cells (data not shown).
Role of TSLP in IL-32-induced macrophage-like cells
differentiation
To investigate the direct role of TSLP in IL-32-induced
macrophage-like cells differentiation, THP-1 cells were sti-
mulated with recombinant TSLP. As shown in Figure 4A,
Figure 1 IL-32-induced mRNA expressions and protein production of TSLP in THP-1 cells. THP-1 cells (3 × 106) were treated with IL-32 (0.01,
0.1, and 1 μg/ml) or LPS (10 ng/ml) for 5 h. The TSLP mRNA expression was measured by the RT-PCR (A) and real-time PCR (B) method. (C) THP-1 cells
(1 × 105) were stimulated with IL-32 (0.1 μg/ml) for various times. (D) THP-1 cells (3 × 105) were stimulated with IL-32 (0.01, 0.1, and 1 μg/ml) or LPS for
24 h. The production of TSLP in the supernatant was measured by the ELISA method. (E) The production of IL-1b in the supernatant was measured by
the ELISA method. (F) PBMCs (3 × 105) were stimulated with IL-32 (0.1, and 1 μg/ml) for 24 h. The production of TSLP in the supernatant was
measured by the ELISA method. Each datum represents the mean ± SEM of three independent experiments. Blank, unstimulated cells. *P < 0.05;
significantly different from unstimulated cells’ value. ELISA, enzyme-linked immunosorbent assay; IL, interleukin; LPS, lipopolysaccharide; PBMC,
peripheral blood mononuclear cells; RT-PCR, reverse transcriptase polymerase chain reaction; TSLP, thymic stromal lymphopoietin.
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recombinant TSLP significantly increased CD11b and
CD14 mRNA expression but increased CD11b and CD14
mRNA expression were reduced by neutralizing anti-
TSLP antibodies. The expression of CD14 mRNA by
TSLP is higher than that of CD11b. Therefore, we exam-
ined the level of CD14 protein expression by TSLP. TSLP
also increased expression of CD14 protein (Figure 4B).
TSLP signals via TSLP receptor (TSLPR), a heterodimer of
the IL-7 receptor alpha chain (IL-7Ra) and the TSLPR
chain supports differentiation and survival of various
immune cells such as DC, T cells, and B cells [28]. TSLPR,
which is expressed by myeloid DC, monocytes, preacti-
vated T cells, natural killer cells, and mast cells [19]. As
shown in Figure 4C, TSLPR was expressed in THP-1 cells.
In order to confirm whether differentiation of THP-1 cells
was mediated by TSLP, we depleted TSLP in THP-1 cells
Figure 2 IL-32-induced TSLP production and mRNA expression via activation of caspase-1 and NF-B. (A) Cells (3 × 106) were treated with
IL-32 (0.01, 0.1, and 1 μg/ml) or LPS (10 ng/ml) for 2 h. Caspase-1 and nuclear NF-B were determined by Western blot analysis. (B) Cells (3 × 106) were
treated with caspase-1 inhibitor (50 nM) for 1 h and then stimulated with IL-32 (0.1 μg/ml) or LPS (10 ng/ml) for 2 h. Caspase-1 activity was
determined by a colorimetric kit. (C) Cells (3 × 105) were treated with caspase-1 inhibitor (50 and 500 nM) for 1 h and then stimulated with IL-32 or
LPS for 24 h. TSLP and IL-1b production was determined by ELISA method. (D) Cells were treated with PDTC (10 μM) for 1 h and then stimulated with
IL-32 or LPS for 5 h. The mRNA expressions TSLP were measured by the RT-PCR method (upper). The NF-B-luciferase activity was assayed by
luciferase assay (lower). Blank, unstimulated cells; Cas inhi, caspase-1 inhibitor 50 nM. *P < 0.05; significantly different from the unstimulated cells’ value,
**P < 0.05; significantly different from the IL-32 or LPS-stimulated cells’ value. ELISA, enzyme-linked immunosorbent assay; IL, interleukin; LPS,
lipopolysaccharide; NF-B, nuclear factor-B; PBMC, peripheral blood mononuclear cells; PDTC, pyrrolidine dithiocarbamate; RT-PCR, reverse
transcriptase polymerase chain reaction; TSLP, thymic stromal lymphopoietin.
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Figure 3 IL-32-induced THP-1 differentiation via activation of caspase-1. THP-1 cells were treated with recombinant IL-32 (0.1 μg/ml) or
caspase-1 inhibitor (50 nM) for 6 days in the absence of FBS. (A) Individual THP-1 cells were photographed. (B) Real-time PCR of macrophage
markers, CD11b and CD14 after simulation of THP-1 cells. (C) FACS analysis of protein expression of macrophage markers, CD11b and CD14.
Blank, unstimulated cells; Cas-1 inhi, caspase-1 inhibitor. *P < 0.05; significantly different from the unstimulated cells’ value, **P < 0.05;
significantly different from the IL-32-stimulated cells’ value. (Original magnification × 400). FACS, fluorescence-activated cell sorter; FBS, fetal
bovine serum; IL, interleukin; PCR, polymerase chain reaction.
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using TSLP siRNA (TSLP SMARTpool, Dharmacon Inc.,
Chicago, IL, USA). Messenger RNA analysis by RT-PCR
revealed that TSLP was reduced (Figure 4C). The expres-
sions of CD11b and CD14 were also decreased by TSLP
siRNA (Figure 4D and 4E). Confocal laser scanning micro-
scopic analysis clearly demonstrated that the enhanced
CD11b and CD14 protein expressions were induced by
treatment with IL-32, but it was markedly blocked by
TSLP siRNA (Figure 4E).
Effect of BT and CS on IL-32 or LPS-induced TSLP
production and mRNA expression
Chondroprotective drugs such as BT and CS is used for
the treatment of arthritis such as RA and osteoarthritis.
Figure 4 TSLP increased the expression of CD11b and CD14. THP-1 cells (3 × 105) were treated with IL-32 (0.1 μg/ml), recombinant TSLP (20
ng/ml), or TSLP neutralizing antibodies (1 μg/ml) for 6 days in RPMI1640 containing 10% FBS. (A) Total RNA was assayed by real-time PCR for
CD11b and CD14. (B) CD14 was determined by Western blot analysis. THP-1 cells were transfected with TSLP siRNA. Transfected THP-1 cells (3 ×
105) were treated with IL-32 (0.1 μg/ml) or recombinant TSLP (20 ng/ml) for 6 days. (C) The total RNA was assayed by RT-PCR analysis for TSLPR
and TSLP mRNA. (D) Real-time PCR of macrophage markers, CD11b and CD14 after simulation of THP-1 cells. (E) CD11b (red) and CD14 (green)
were examined with a confocal laser scanning microscope. Blank, unstimulated cells; Neu ab, TSLP neutralizing antibodies. *P < 0.05; significantly
different from the unstimulated cells’ value, **P < 0.05; significantly different from the TSLP-stimulated cells’ value. (Original magnification × 600).
FBS, fetal bovine serum; IL, interleukin; RT-PCR, reverse transcriptase polymerase chain reaction; TSLP(R), thymic stromal lymphopoietin (receptor).
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We assessed the regulatory effect of BT and CS on IL-
32 or LPS-induced TSLP production and mRNA expres-
sion. The results showed that BT and CS significantly
inhibited IL-32 or LPS-induced TSLP production and
mRNA expression (Figures 5A to 5D, P < 0.05). CS
dose-dependently inhibited LPS-induced TSLP produc-
tion. BT or CS did not affect TSLP production by itself.
Effect of BT and CS in IL-32 or LPS-induced caspase-1 and
NF-B activation
We investigated whether BT and CS would influence the
activation of caspase-1 induced by IL-32 or LPS in THP-1
cells. Western blot analysis for caspase-1 was performed.
Caspase-1 activation by IL-32 or LPS was decreased by the
treatment of BT or CS (Figure 5E and 5F). We also esti-
mated the effect of BT and CS on caspase-1 activation
using a caspase-1 assay kit. Once again, this showed that
caspase-1 activity was significantly inhibited by the treat-
ment of BT or CS (Figure 5G and 5H, P < 0.05). The
expression of TSLP mRNA was regulated by the transcrip-
tion factor, NF-B [26]. Because the suppression of NF-B
is linked with anti-inflammation, we postulated that BT
and CS mediate its effects at least partly through the sup-
pression of NF-B activation. To assess the regulatory
mechanism of BT and CS on TSLP mRNA expression, we
examined the regulatory effect of BT and CS on the trans-
location of NF-B into the nucleus. The stimulation with
IL-32 or LPS increased translocated levels of NF-B in the
nucleus but the translocated levels of NF-B were sup-
pressed by the treatment of BT or CS (Figure 5E and 5F).
Effect of BT and CS in IL-32-induced macrophage-like
cells differentiation
Finally, we assessed the regulatory effect of BT and CS in
IL-32-induced macrophage-like cells differentiation. The
expression of CD11b and CD14 mRNA was analyzed by
real-time PCR. BT and CS inhibited expressions of CD11b
and CD14 mRNA and protein (Figure 6A and 6B). Confo-
cal laser scanning microscopic analysis clearly demon-
strated that the enhanced expression of CD11b and CD14
was induced by the treatment of IL-32, but it was mark-
edly blocked by the treatment of BT or CS (Figure 6C).
BT and CS significantly inhibited IL-32-induced TSLP
mRNA expression (Figures 6D, P < 0.05).
Discussion
In the present study, we demonstrated that IL-32
induced the TSLP production and mRNA expression via
activation of caspase-1 and NF-B. IL-32 and TSLP also
increased the differentiation of THP-1 cells. In addition,
CS and BT inhibited the differentiation of THP-1 cells
through inhibition of TSLP production and caspase-1
activation.
IL-32 plays an important role in host defense against
microorganisms including Mycobacterium, HIV, and
influenza [13,29-31]. IL-32 has also been implicated in sev-
eral inflammatory disorders, including rheumatoid arthri-
tis, Crohn’s disease, atopic dermatitis, chronic obstructive
pulmonary disease, and allergic rhinitis [9,11,12,32,33].
IL-32 expression is related with disease severity in these
conditions. Recently, we have been shown that silencing of
endogenous IL-32 results in the reduction of IL-6, IL-8,
TNF-a, and vascular endothelial growth factor (VEGF)
[11]. TSLP produced the IL-5, IL-6, IL-13, and granulocyte
macrophage colony-stimulating factor from mast cells
[18]. TSLP expression correlates with markers of inflam-
mation. TSLP-induced immune activation increased the
joint destruction, because TSLPR-/-mice displayed
decreased cartilage and bone erosion, decreased number
of tartrate-resistant acid phophatase-positive osteoclasts,
and reduced local expression of factors that are involved
in tissue destruction [15]. Block of TSLP reduced the
severity of collagen-induced arthritis [15]. From this, we
can presuppose that TSLP produced by IL-32 plays an
important role in expression of inflammatory cytokines.
These properties suggest that IL-32-induced TSLP might
play an important role in the amplification of inflamma-
tory reactions such as RA. Future studies will be required
to investigate whether TSLP acts as an endogenous regula-
tor of proinflammatory cytokine production in monocytes.
It has been shown that IL-32 potentiates one or more
of the intracellular pathways induced by NOD ligands.
Synthetic muramyl dipeptide engagement of NOD2 results
in the activation of two signaling pathways. First, NOD2
activates the serine/threonine kinase receptor-interacting
protein 2/RICK/CARDIAK, and this leads to NF-B acti-
vation and transcription of proinflammatory cytokine
genes such as those encoding TNF-a, IL-1b, and IL-6
[34]. Second, the CARD domain of NOD-like receptors
proteins interacts with caspase-1 and 5, and this interac-
tion results in the processing of cytokine precursors such
as pro-IL-1b and pro-IL-18 [34]. In this study, IL-32
increased the caspase-1 and NF-B activation in THP-1
cells. Caspase-1 inhibitor or NF-B inhibitor reduced the
IL-32-induced TSLP production and mRNA expression.
Taken together, these reports imply that IL-32 induces
TSLP production and mRNA expression in THP-1 cells
through a signaling cascade downstream of the caspase-1
and NF-B activation.
Both the innate and acquired immune systems rely
heavily upon the effector and regulatory activities of
monocytes and macrophages [35]. Differentiation of mye-
loid cells involves broad-based and tightly regulated
changes in gene expression induced in response to
diverse cytokines, growth factors and other agonists
[36,37]. Expression of CD11b and CD14 is upregulated
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Figure 5 BT and CS inhibited the IL-32 or LPS-induced TSLP production and mRNA expression through the inhibition of caspase-1
and NF-B activation. THP-1 cells (3 × 105) were treated with BT (100 μg/ml) and CS (0.1, 1, and 10 μg/ml) for 2 h and then stimulated with
LPS (10 ng/ml, (A) or IL-32 (0.1 μg/ml, (B) for 24 h. The production of TSLP in the supernatant was measured by the ELISA method. (C and D)
THP-1 cells (3 × 106) were treated with BT or CS for 5 h. The mRNA expressions of TSLP were measured by the RT-PCR method. THP-1 cells (3 ×
106) were treated with BT (100 μg/ml) and CS (0.1, 1, and 10 μg/ml) for 2 h and then stimulated with IL-32 (0.1 μg/ml) or LPS (10 ng/ml) for 2 h.
(E and F) Caspase-1 and NF-B were determined by Western blot analysis. (G and H) Caspase-1 activity was determined by a colorimetric kit. *P
< 0.05; significantly different from the unstimulated cells’ value, **P < 0.05; significantly different from the IL-32 or LPS-stimulated cells’ value. BT,
BaekJeol-Tang; CS, chondroitin sulfate; ELISA, enzyme-linked immunosorbent assay; IL, interleukin; LPS, lipopolysaccharide; NF-B, nuclear factor-
B; RT-PCR, reverse transcriptase polymerase chain reaction; TSLP, thymic stromal lymphopoietin.
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during myeloid cell differentiation. Myeloid zinc finger-1 is
involved downstream of phosphatidylinositide 3-kinase in a
calcitriol-induced signaling pathway leading to myeloid cell
differentiation and activation of CD11b and CD14 [37].
Recent studies by Netea and colleagues reported that IL-32
induced a consistent increase in the expression of both
CD1a and CD14 [27]. TSLP is capable of activating dendri-
tic cells to promote Th2 immune responses. TSLP has also
been shown to directly promote Th2 differentiation of
naïve CD4 (+) T cell and activate natural killer T cells,
basophils and other innate immune cells at the initial stage
of inflammation [38]. We also observed that IL-32 induces
differentiation of THP-1 cells into macrophage-like cell.
Netea et al., showed caspase-3 activation, but not caspae-1,
-8, -9, plays an important role in monocyte differentiation
[27]. However, we investigated that caspase-1 inhibitor
reduced the CD11b and CD14 expression through the
inhibition of TSLP production. We also showed that TSLP
siRNA inhibited the monocyte differentiation. For that rea-
son, we suggest that blockade of IL-32 and TSLP signaling
may be effective in prevention and treatment in models of
inflammatory arthritis.
The suppressing of TSLP production signaling in THP-1
cells may be a useful tool to reduce monocyte differentia-
tion in inflammatory conditions. CS belongs to the class of
natural complex polysaccharides and is an unbranched,
Figure 6 BT and CS inhibited the IL-32-induced THP-1 differentiation. THP-1 cells (3 × 105) were treated with BT (100 μg/ml) or CS (1 μg/ml)
for 2 h and then stimulated with IL-32 (0.1 μg/ml) for 6 days in the absence of FBS. (A) Real-time PCR of macrophage markers, CD11b and CD14
mRNA after simulation of THP-1 cells. (B) CD14 and caspase-1 were determined by Western blot analysis. (C) CD11b (red) and CD14 (green) were
examined with confocal laser-scanning microscope. (D) The mRNA expressions of TSLP were measured by the real-time PCR. Blank, unstimulated
cells. *P < 0.05; significantly different from the unstimulated cells’ value, **P < 0.05; significantly different from the IL-32-stimulated cells’ value.
(Original magnification × 600). BT, BaekJeol-Tang; CS, chondroitin sulfate; FBS, fetal bovine serum; PCR, polymerase chain reaction; TSLP, thymic
stromal lymphopoietin.
Jeong et al. Arthritis Research & Therapy 2012, 14:R259
http://arthritis-research.com/content/14/6/R259
Page 10 of 12
polydisperse, complex macromolecule extracted and puri-
fied from various tissues [39]. It is a useful therapeutic
agent in diseases such as inflammatory bowel diseases,
artherosclerosis, Parkinson’s and Alzheimer’s diseases,
multiple sclerosis, amyotrophic lateral sclerosis, rheuma-
toid arthritis, and systemic lupus erythematosus [40]. CS
diminishes the expression of inflammatory proteins via
inhibiting of NF-B nuclear translocation in chondrocyte,
synovial macrophages, synoviocytes, and peripheral blood
mononuclear cells [40]. In previous studies, David-Raoudi
et al., reported that CS increases hyaluronan production
through upregulation of the expression of hyaluronan
synthases [39]. BT, a traditional Korean medicine, has long
been prescribed as a treatment for joint diseases to protect
injured chondrocytes. However, effect of these drugs has
not been elucidated on TSLP production and monocyte
differentiation. In this study, we showed that BT or CS sig-
nificantly inhibited the production of TSLP, activation of
caspase-1 and NF-B, and differentiation of monocytes in
THP-1 cells. Therefore, our finding provides new evidence
that chondroprotective effect caused by the treatment of
BT and CS is related to the inhibition of TSLP production
and monocyte differentiation.
Conclusions
In conclusion, we show for the first time that IL-32
induces TSLP production by increasing NF-B and cas-
pase-1 activation. IL-32-induced TSLP induces differentia-
tion of monocytes into macrophage-like cells with
characteristic surface markers (CD11b and CD14). To our
knowledge, this is also the first study to demonstrate that
chondroprotective effect of BT and CS is accompanied by
a regulation of TSLP production. Our results have demon-
strated an essential role for the IL-32/TSLP pathway in
RA. Further investigation is necessary to determine other
possible mechanisms of IL-32 and TSLP and to apply it
clinically in RA and other inflammatory diseases.
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